{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:09:56Z","timestamp":1788948596506,"version":"build-2803163510"},"reference-count":56,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. Neoadjuvant cisplatin-based chemotherapy has been used for decades to lower recurrence rates but a significant proportion of patients still have disease relapse. Recently, immune-checkpoint inhibitors (ICIs) have been evaluated for patients with MIBC, with some success. This has led to regulatory approval of adjuvant nivolumab, sandwich perioperative durvalumab and sandwich perioperative pembrolizumab with enfortumab vedotin. This review summarizes the history of practice-informing and practice-changing neoadjuvant, adjuvant and sandwich perioperative application of ICIs for MIBC, looks ahead to the promising developments in other ICI-based sandwich perioperative regimens, and highlights controversies surrounding overtreatment versus undertreatment and the need for predictive biomarkers.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-perioperative-immune-checkpoint-inhibitors-for-muscle-invasive-bladder-cancer\n\nThis article is part of the The changing landscape and future of perioperative management of localized bladder cancer Special Issue: https:\/\/www.drugsincontext.com\/special_issues\/the-changing-landscape-and-future-of-perioperative-management-of-localized-bladder-cancer<\/jats:p>","DOI":"10.7573\/dic.2025-9-1","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:26:53Z","timestamp":1781875613000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer"],"prefix":"10.7573","volume":"15","author":[{"given":"Albert","family":"Jang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby L","family":"Grier","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Y","family":"Sheng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Bari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Garcia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Brown","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tGrossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u2013866. https:\/\/doi. org\/10.1056\/NEJMoa022148","DOI":"10.1056\/NEJMoa022148"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tDash A, Pettus JAt, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113(9):2471\u20132477. https:\/\/doi.org\/10.1002\/ cncr.23848","DOI":"10.1002\/cncr.23848"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPlimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895\u20131901. https:\/\/doi. org\/10.1200\/jco.2013.53.2465","DOI":"10.1200\/JCO.2013.53.2465"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tChoueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889\u20131894. https:\/\/doi.org\/10.1200\/jco.2013.52.4785","DOI":"10.1200\/JCO.2013.52.4785"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tPfister C, Gravis G, Fl\u00e9chon A, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013\u20132022. https:\/\/doi. org\/10.1200\/jco.21.02051","DOI":"10.1200\/JCO.21.02051"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tPfister C, Gravis G, Flechon A, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25(2):255\u2013264. https:\/\/doi.org\/10.1016\/s1470-2045(23)00587-9","DOI":"10.1016\/S1470-2045(23)00587-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tGalsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20132438. https:\/\/doi.org\/10.1200\/jco.2011.34.8433","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tGalsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann oncol. 2012;23(2):406\u2013410. https:\/\/doi. org\/10.1093\/annonc\/mdr156","DOI":"10.1093\/annonc\/mdr156"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tGalluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tZhang L, Zhang R, Jin D, et al. Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer. Br J Cancer. 2024;130(7):1221\u20131231. https:\/\/doi.org\/10.1038\/s41416-024-02598-7","DOI":"10.1038\/s41416-024-02598-7"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tBasile G, Bandini M, Gibb EA, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of pure-01 trial. Clin Cancer Res. 2022;28(23):5107\u20135114. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2158","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tSzabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022;82(2):212\u2013222. https:\/\/doi.org\/10.1016\/j. eururo.2022.04.013","DOI":"10.1016\/j.eururo.2022.08.037"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tvan Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u20131844. https:\/\/doi.org\/10.1038\/s41591-020-1085-z","DOI":"10.1038\/s41591-020-1085-z"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tGuercio BJ, Pietzak EJ, Ravichandran V, et al. Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer. Clin Cancer Res. 2026;32(8):1434\u20131444. https:\/\/doi. org\/10.1158\/1078-0432.Ccr-25-3771","DOI":"10.1158\/1078-0432.CCR-25-3771"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tGao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845\u20131851. https:\/\/doi.org\/10.1038\/s41591-020-1086-y","DOI":"10.1038\/s41591-020-1086-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tGrande E, Guerrero F, Puente J, et al. DUTRENEO trial: a randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol. 2020;38(15 Suppl.):5012. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tFunt SA, Lattanzi M, Whiting K, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40(12):1312\u20131322. https:\/\/doi.org\/10.1200\/jco.21.01485","DOI":"10.1200\/JCO.21.01485"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tRose TL, Harrison MR, Deal AM, et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J Clin Oncol. 2021;39(28):3140\u20133148. https:\/\/doi.org\/10.1200\/jco.21.01003","DOI":"10.1200\/JCO.21.01003"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tBrown J, Kaimakliotis HZ, Kelly WK, et al. HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. J Clin Oncol. 2023;41(6 Suppl.):448. https:\/\/doi.org\/10.1200\/ JCO.2023.41.6_suppl.448","DOI":"10.1200\/JCO.2023.41.6_suppl.448"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tGupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38(6 Suppl.):439. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.439","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tGupta S, Makarov V, Sonpavde GP, et al. Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy. J Clin Oncol. 2023;41(6 Suppl.):559. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.559","DOI":"10.1200\/JCO.2023.41.6_suppl.559"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tXu A, Xu P, Chen C, et al. A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2023;41(16 Suppl.):e16602. https:\/\/ doi.org\/10.1200\/JCO.2023.41.16_suppl.e16602","DOI":"10.1200\/JCO.2023.41.16_suppl.e16602"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tBlanc J, Carnot A, Barth\u00e9l\u00e9my P, et al. Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. J Immunother Cancer. 2025;13(5):e012045. https:\/\/doi.org\/10.1136\/jitc-2025-012045","DOI":"10.1136\/jitc-2025-012045"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tGhatalia P, Ross EA, Zibelman MR, et al. Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): integrated analysis of the RETAIN trials. J Clin Oncol. 2026;44(7 Suppl.):LBA632. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.LBA632","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA632"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tNecchi A, Guerrero-Ramos F, Crispen PL, et al. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. Lancet Oncol. 2025;26(10):1312\u20131322. https:\/\/doi.org\/10.1016\/s1470-2045(25)00358-4","DOI":"10.1016\/S1470-2045(25)00358-4"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tRaychaudhuri R, Khaki AR, Redman MW, et al. Neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in nonurothelial histologic subtypes of muscle-invasive bladder cancer: a phase 2 trial. Eur Urol. 2025;88(6):559\u2013563. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.002","DOI":"10.1016\/j.eururo.2025.07.002"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tNeoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202\u2013205; discussion 205\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tGalsky MD, Gschwend JE, Milowsky MI, et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann Oncol. 2026;37(1):69\u201378. https:\/\/ doi.org\/10.1016\/j.annonc.2025.09.139","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tApolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726","DOI":"10.1056\/NEJMe2411485"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tBellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525\u2013537. https:\/\/doi.org\/10.1016\/s1470-2045(21)00004-8","DOI":"10.1016\/S1470-2045(21)00004-8"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tPowles T, Assaf ZJ, Degaonkar V, et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur Urol. 2024;85(2):114\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.007","DOI":"10.1016\/j.eururo.2023.06.007"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tPowles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393(24):2395\u20132408. https:\/\/doi.org\/10.1056\/NEJMoa2511885","DOI":"10.1056\/NEJMoa2511885"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tDyrskj\u00f8t L, Birkenkamp-Demtr\u00f6der K, Nordentoft I, et al. ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial. Ann Oncol. 2026;37(5):712\u2013724. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.018","DOI":"10.1016\/j.annonc.2025.12.018"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tCathomas R, Rothschild SI, Hayoz S, et al. Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase II trial SAKK 06\/17. J Clin Oncol. 2023;41(33):5131\u20135139. https:\/\/doi.org\/10.1200\/jco.23.00363","DOI":"10.1200\/JCO.23.00363"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tPowles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","DOI":"10.1056\/NEJMoa2408154"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tGalsky MD, Heijden MSVD, Catto JWF, et al. Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. J Clin Oncol. 2025;43(5 Suppl.):659. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.659","DOI":"10.1200\/JCO.2025.43.5_suppl.659"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tGalsky MD, Hoimes CJ, Necchi A, et al. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303. Future Oncol. 2021;17(24):3137\u20133150. https:\/\/doi.org\/ 10.2217\/fon-2021-0273","DOI":"10.2217\/fon-2021-0273"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tSonpavde G, Necchi A, Gupta S, et al. ENERGIZE: a phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 2020;16(2):4359\u2013 4368. https:\/\/doi.org\/10.2217\/fon-2019-0611","DOI":"10.2217\/fon-2019-0611"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tMercinelli C, Moschini M, Cigliola A, et al. First results of NURE-combo: a phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer. J Clin Oncol. 2024;42(35):4196\u20134205. https:\/\/doi.org\/10.1200\/jco.24.00576","DOI":"10.1200\/JCO.24.00576"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tVulsteke C, Adra N, Danchaivijitr P, et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N Engl J Med. 2026;394(13):1257\u20131269. https:\/\/doi.org\/10.1056\/NEJMoa2511674","DOI":"10.1056\/NEJMoa2511674"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tGalsky MD, Valderrama BP, Maruzzo M, et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. J Clin Oncol. 2026;44(7 Suppl.):LBA630. https:\/\/doi. org\/10.1200\/JCO.2026.44.7_suppl.LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tPowles T, Drakaki A, Teoh JY-C, et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). J Clin Oncol. 2022;40(6 Suppl):TPS579. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tDrakaki A, Powles TB, Wang Y, et al. 1970MO circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial. Ann Oncol. 2024;35:S1140. https:\/\/doi. org\/10.1016\/j.annonc.2024.08.2055","DOI":"10.1016\/j.annonc.2024.08.2055"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tSheng X, Zhang C, Ji Y, et al. Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial. J Clin Oncol. 2025;43(5 Suppl.):665. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.665","DOI":"10.1200\/JCO.2025.43.5_suppl.665"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tPowles T, Tagawa S, Vulsteke C, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025;36(5):561\u2013571. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.011","DOI":"10.1016\/j.annonc.2025.01.011"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tNecchi A, Maiorano BA, de Jong JJ, et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 2026;27(4):442\u2013451. https:\/\/doi.org\/10.1016\/s1470-2045(26)00050-1","DOI":"10.1016\/S1470-2045(26)00050-1"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tLiu Z, Chen C, Yin J, Cong X, Liu Z. Changing landscape of first-line treatment for locally advanced or metastatic urothelial carcinoma: the progression from platinum-based chemotherapy to platinum-free therapy. Front Immunol. 2025;16:1604395. https:\/\/doi.org\/10.3389\/fimmu.2025.1604395","DOI":"10.3389\/fimmu.2025.1604395"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tHolzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ SUO guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3\u201310. https:\/\/doi.org\/10.1097\/ju.0000000000003981","DOI":"10.1097\/JU.0000000000003981"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tBajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","DOI":"10.1056\/NEJMoa2034442"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tHou\u00e9d\u00e9 N, Chevallier T, Audenet F, et al. Safety and efficacy of neoadjuvant durvalumab plus gemcitabine\/ cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT-GETUG V08 trial. J Clin Oncol. 2025;43(13):1578\u20131586. https:\/\/doi.org\/10.1200\/jco-25-00179","DOI":"10.1200\/JCO-25-00179"},{"key":"ref50","unstructured":"51.\tGalsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u20132834. https:\/\/doi. org\/10.1038\/s41591-023-02568-1"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tAchard V, Abdel-Aty H, Santana VD, et al. Combining radiation therapy with immune checkpoint inhibitors for the management of muscle-invasive bladder cancer: a comprehensive systematic review from the Y-ECI ROSC EORTC group. Pract Radiat Oncol. 2025;15(6)610\u2013624. https:\/\/doi.org\/10.1016\/j.prro.2025.05.004","DOI":"10.1016\/j.prro.2025.05.004"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tTamalunas A, Aydogdu C, Unterrainer LM, et al. The vanishing clinical value of PD-L1 status as a predictive biomarker in the first-line treatment of urothelial carcinoma of the bladder. Cancers. 2024;16(8):1536. https:\/\/doi. org\/10.3390\/cancers16081536","DOI":"10.3390\/cancers16081536"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tBellmunt J, Russell BM, Szabados B, Valderrama BP, Nadal R. Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma. Am Soc Clin Oncol Educ Book. 2025;45(2):e471912. https:\/\/doi. org\/10.1200\/edbk-25-471912","DOI":"10.1200\/EDBK-25-471912"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tHeijden MSVD, Galsky MD, Joshi R, et al. Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J Clin Oncol. 2026;44(7 Suppl.):636. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.636","DOI":"10.1200\/JCO.2026.44.7_suppl.636"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tPowles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432\u2013437. https:\/\/doi.org\/10.1038\/s41586-021-03642-9","DOI":"10.1038\/s41586-021-03642-9"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/06\/dic.2025-9-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:48:55Z","timestamp":1788947335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/perioperative-immune-checkpoint-inhibitors-for-muscle-invasive-bladder-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-9-1","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"dic.2025-9-1"}}